These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 32948458)
1. Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation. Roex MCJ; Wijnands C; Veld SAJ; van Egmond E; Bogers L; Zwaginga JJ; Netelenbos T; von dem Borne PA; Veelken H; Halkes CJM; Falkenburg JHF; Jedema I Cytotherapy; 2021 Jan; 23(1):46-56. PubMed ID: 32948458 [TBL] [Abstract][Full Text] [Related]
2. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. Loeff FC; van Egmond EHM; Moes DJAR; Wijnands C; Von Dem Borne PA; Veelken H; Falkenburg JHF; Jedema I; Halkes CJM Transpl Immunol; 2019 Dec; 57():101209. PubMed ID: 31207283 [TBL] [Abstract][Full Text] [Related]
3. Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab "in the bag". Davison GM; Opie JJ; Davids SFG; Mohammed R; Novitzky N Transpl Immunol; 2024 Jun; 84():102045. PubMed ID: 38641148 [TBL] [Abstract][Full Text] [Related]
4. High Mutation Frequency of the Loeff FC; Falkenburg JHF; Hageman L; Huisman W; Veld SAJ; van Egmond HME; van de Meent M; von dem Borne PA; Veelken H; Halkes CJM; Jedema I J Immunol; 2018 Mar; 200(6):2199-2208. PubMed ID: 29427418 [TBL] [Abstract][Full Text] [Related]
5. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis. Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451 [TBL] [Abstract][Full Text] [Related]
6. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation. Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H Front Immunol; 2019; 10():1997. PubMed ID: 31507601 [TBL] [Abstract][Full Text] [Related]
7. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596 [TBL] [Abstract][Full Text] [Related]
9. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. D'Sa S; Peggs K; Pizzey A; Verfuerth S; Thuraisundaram D; Watts M; White H; Hale G; Waldmann H; Goldstone A; Mackinnon S; Yong K Br J Haematol; 2003 Oct; 123(2):309-22. PubMed ID: 14531914 [TBL] [Abstract][Full Text] [Related]
10. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease. Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF Front Immunol; 2019; 10():334. PubMed ID: 30894856 [TBL] [Abstract][Full Text] [Related]
11. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients. Arnold DE; MacMath D; Seif AE; Heimall JR; Wang Y; Monos D; Grupp SA; Bunin NJ Transplant Cell Ther; 2021 Feb; 27(2):169.e1-169.e9. PubMed ID: 33830028 [TBL] [Abstract][Full Text] [Related]
12. Lower incidence of grade II-IV acute Graft-versus-Host-Disease in pediatric patients recovering with high Vδ2+ T cells after allogeneic stem cell transplantation with unmanipulated bone marrow grafts: a prospective single-center cohort study. Müller T; Alasfar L; Preuß F; Zimmermann L; Streitz M; Hundsdörfer P; Eggert A; Schulte J; von Stackelberg A; Oevermann L Front Immunol; 2024; 15():1433785. PubMed ID: 39136029 [TBL] [Abstract][Full Text] [Related]
13. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells. Grimaldi F; Potter V; Perez-Abellan P; Veluchamy JP; Atif M; Grain R; Sen M; Best S; Lea N; Rice C; Pagliuca A; Mufti GJ; Marsh JCW; Barber LD Biol Blood Marrow Transplant; 2017 Feb; 23(2):293-299. PubMed ID: 27816648 [TBL] [Abstract][Full Text] [Related]
14. A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors. Kalwak K; Mosoń I; Cwian J; Gorczyńska E; Toporski J; Turkiewicz D; Latos-Grazyńska E; Chybicka A Transplant Proc; 2003 Jun; 35(4):1551-5. PubMed ID: 12826218 [TBL] [Abstract][Full Text] [Related]
15. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation. Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461 [TBL] [Abstract][Full Text] [Related]
16. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801 [TBL] [Abstract][Full Text] [Related]
17. CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen. Woelfinger P; Epp K; Schaefer L; Kriege D; Theobald M; Bopp T; Wagner-Drouet EM Br J Haematol; 2020 Oct; 191(2):253-262. PubMed ID: 32410220 [TBL] [Abstract][Full Text] [Related]
19. Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag). Novitzky N; Davison G; Abdulla R; Mowla S Biol Blood Marrow Transplant; 2013 Dec; 19(12):1753-9. PubMed ID: 24120379 [TBL] [Abstract][Full Text] [Related]
20. Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors. Rådestad E; Wikell H; Engström M; Watz E; Sundberg B; Thunberg S; Uzunel M; Mattsson J; Uhlin M J Immunol Res; 2014; 2014():578741. PubMed ID: 25371909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]